Heather A. Wakelee
Heather Wakelee is a lung cancer leader who led the first adjuvant immunotherapy trial to change practice.
Heather Wakelee is a thoracic medical oncologist and the principal investigator of IMpower010, the adjuvant atezolizumab trial, and of KEYNOTE-671 (perioperative pembrolizumab). Past president of the International Association for the Study of Lung Cancer.
| Title | Journal | Year |
|---|---|---|
| Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial | Lancet | 2021 |
| Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2023 |
Pages like this
not linked directly; found by shared links- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Atezolizumab, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeaRandomise a cheap antihistamine alongside immunotherapy
Shares Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PairingPD-1 blockade + VEGF inhibition
Shares Atezolizumab, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- TechnologyMUSK (Stanford, vision-language pathology)
Shares Stanford Health Care / Stanford Cancer Institute, Non-small-cell lung cancer.
- TrialHARMONi-3
Shares Pembrolizumab, Non-small-cell lung cancer.
- PersonMaximilian Diehn
Shares Stanford Health Care / Stanford Cancer Institute, Non-small-cell lung cancer.
- IdeaImmunotherapy downstaging to transplant with a safe washout
Shares Atezolizumab, Immune checkpoint inhibitors.
- PersonTasuku Honjo
Shares Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.